Livzon Pharmaceutical Group Inc. (HKG:1513)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.40
+1.08 (3.95%)
At close: Mar 6, 2026
11.81%
Market Cap 31.72B
Revenue (ttm) 12.95B
Net Income (ttm) 2.34B
Shares Out n/a
EPS (ttm) 2.61
PE Ratio 13.55
Forward PE 12.54
Dividend 1.20 (4.24%)
Ex-Dividend Date Jun 13, 2025
Volume 735,000
Average Volume 795,788
Open 27.44
Previous Close 27.32
Day's Range 27.44 - 28.40
52-Week Range 24.85 - 41.85
Beta 0.37
RSI 44.26
Earnings Date Mar 24, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride... [Read more]

Sector Healthcare
Founded 1985
Employees 9,067
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1513
Full Company Profile

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.